AAV: Proactively Addressing the Challenge, While Celebrating the Highlights
28 April 2023
Katja Betts, CEO at PROGEN, discusses the core issues affecting biotechs working with AAV and how these could be addressed at both the individual team and industry-wide levels.
Katja begins by introducing the challenges facing biotechs within AAV, and explores the possibility for devising standards for the field. Katja continues to explore challenges that occur when scaling up AAV operations, before sharing her top tips for developing AAV.
Finally, Katja discusses her AAV ‘headline highlights’ from the past year or so, and suggests what we might be able to expect from the next 5 years.
This interview has been produced in partnership with PROGEN and was recorded at Advanced Therapies Week 2023.
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
8 June 2023
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
7 June 2023
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
5 June 2023